DCGI Frames Rules For Safety, Quality Of Imported Cosmetics

New Delhi:  No cosmetics can be imported unless the ‘use-by’ date is at least six months from the date of import, the Drugs Controller General of India (DCGI) said.

The regulator, issuing instructions for importing cosmetics, also banned imports of cosmetics containing hexachlorophene and those that have been tested on animals after 12 November 2014.

DCGI banned animal testing for makeup products and manufacturers and importers on that day.

Hexachlorophene is a topical antibacterial cleanser, used to clean the skin before surgery to prevent the spread of infection. It is banned for cosmetic use.

“No cosmetic, the manufacture, sale or distribution of which is prohibited in the country of origin, shall be imported under the same name or under any other name except for the purpose of examination, test or analysis,” the guidance document for zonal, sub-zonal and port offices stated.

According to industry estimates, India’s cosmetic market was valued at $8.1 billion in 2023 and is expected to reach $18.4 billion by 2032.

It said that any person who intends to import a new cosmetic needs to apply to the Central Licensing Authority with data on safety and effectiveness of the cosmetic.

Notably, beauty cosmetic items are mostly expensive and come in different domestic and international brands. In India, a large number of fake cosmetic items are sold in flea markets or by unauthorized sellers at a cheaper price.

According to the Cosmetic Rules, 2020, no cosmetic may convey any idea which is false or misleading to the intended user.

Earlier, Mint reported that DCGI has issued a new code for drug inspectors to make their inspections, sample collections and permits uniform, predictable and accountable.

It directed drug inspectors to follow a uniform drug sampling method and focus on identifying risks during selection of sample drugs, cosmetics and medical devices moving in the supply chain.

Related Posts

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

The Team Meticulously averted the Risk of Thrombosis, Husband was Donor Delhi/NCR : Doctors at Yashoda Medicity have successfully performed a high-risk kidney transplant in a 28-year-old woman with Antiphospholipid…

Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

Avacta, a UK-based clinical stage biotech, is differentiated clinical-stage oncology specialist, increasingly defined by continuing progress with its second-generation pre|CISION tumour-activated Peptide Drug Conjugate (PDC) platform. The lead Gen Two…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert

Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert

Puresta launches EVERQ, AI-powered skin-health platform

Puresta launches EVERQ, AI-powered skin-health platform

Stem cell therapy for autism only in approved clinical trials: Centre

Stem cell therapy for autism only in approved clinical trials: Centre